Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma

被引：1

作者：

Shah, Jatin J. ^{[1
]}

Feng, Lei ^{[1
]}

Manasanch, Elisabet E. ^{[1
]}

Weber, Donna M. ^{[1
]}

Thomas, Sheeba K. ^{[1
]}

Turturro, Francesco ^{[1
]}

Alexanian, Raymond ^{[1
]}

Shah, Nina ^{[1
]}

Popat, Uday R. ^{[1
]}

Nieto, Yago ^{[1
]}

Bashir, Qaiser ^{[1
]}

Qazilbash, Muzaffar H. ^{[1
]}

Champlin, Richard E. ^{[2
]}

Orlowski, Robert Z. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[31] Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma
Yvette N. Lamb
Drugs, 2020, 80 : 1455 - 1464
[32] Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma
Lamb, Yvette N.
DRUGS, 2020, 80 (14) : 1455 - 1464
[33] A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study
Nooka, Ajay K.
Kaufman, Jonathan L.
Rodriguez, Cesar
Jakubowiak, Andrzej
Efebera, Yvonne
Reeves, Brandi
Wildes, Tanya
Holstein, Sarah A.
Anderson Jr, Larry D.
Badros, Ashraf
Shune, Leyla
Chari, Ajai
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter
FUTURE ONCOLOGY, 2022, 18 (40) : 4443 - 4456
[34] A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
O'Donnell, Elizabeth K.
Mo, Clifton C.
Nadeem, Omar
Yee, Andrew J.
Branagan, Andrew R.
Laubach, Jacob
Gammon, Marilyn T.
Lively, Kathleen J.
Packer, Lisette
Harrington, Cynthia C.
Agyemang, Emerentia
Rosenblatt, Jacalyn
Horick, Nora K.
Richardson, Paul G.
Raje, Noopur
BLOOD, 2022, 140 : 7282 - 7283
[35] Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sara A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Lutska, Yana
Bobba, Padma
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter M.
BLOOD, 2021, 138
[36] A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
O'Donnell, Elizabeth K.
Mo, Clifton C.
Yee, Andrew J.
Nadeem, Omar
Branagan, Andrew R.
Laubach, Jacob
Rosenblatt, Jacalyn
Horick, Nora
Richardson, Paul G.
Raje, Noopur
Cirstea, Diana
BLOOD, 2023, 142
[37] Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update
Voorhees, Peter M.
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Anderson, Larry D.
Nathwani, Nitya
Shah, Nina D.
Efebera, Yvonne A.
Costello, Caitlin L.
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Murphy, Sean
Lutska, Yana
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
de Boer, Carla
Hoehn, Daniela
Lin, Thomas S.
Richardson, Paul G.
BLOOD, 2019, 134
[38] A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
O'Donnell, Elizabeth
Laubach, Jacob P.
Yee, Andrew J.
Huff, Carol Ann
Basile, Frank
Wade, Philip M.
Paba-Prada, Claudia E.
Ghobrial, Irene M.
Schlossman, Robert L.
Couture, Nicole
Doherty, Lauren
Lyons, Hannah
English, Caroline
Munshi, Nikhil
Anderson, Kenneth C.
Richardson, Paul G.
Raje, Noopur
BLOOD, 2014, 124 (21)
[39] Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial
Mai, Elias K.
Bertsch, Uta
Pozek, Ema
Fenk, Roland
Besemer, Britta
Hanoun, Christine
Schroers, Roland
von Metzler, Ivana
Haenel, Mathias
Mann, Christoph
Leypoldt, Lisa B.
Heilmeier, Bernhard
Huhn, Stefanie
Vogel, Sabine K.
Hundemer, Michael
Scheid, Christof
Blau, Igor W.
Luntz, Steffen
Weinhold, Niels
Tichy, Diana
Holderried, Tobias A. W.
Trautmann-Grill, Karolin
Gezer, Deniz
Klaiber-Hakimi, Maika
Mueller, Martin
Shumilov, Evgenii
Knauf, Wolfgang
Michel, Christian S.
Geer, Thomas
Riesenberg, Hendrik
Lutz, Christoph
Raab, Marc S.
Benner, Axel
Hoffmann, Martin
Weisel, Katja C.
Salwender, Hans J.
Goldschmidt, Hartmut
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (11)
[40] A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
O'Donnell, Elizabeth K.
Mo, Clifton C.
Yee, Andrew J.
Nadeem, Omar
Branagan, Andrew R.
Laubach, Jacob P.
Gammon, Marilyn T.
Lively, Kathleen J.
Packer, Lisette
Harrington, Cynthia C.
Agyemang, Emerentia
Spillane, Kerry
LaStofka, Brenton
Rosenblatt, Jacalyn
Raje, Noopur S.
Richardson, Paul G.
BLOOD, 2021, 138

← 1 2 3 4 5 →